company background image
POLB

Poolbeg Pharma AIM:POLB Stock Report

Last Price

UK£0.046

Market Cap

UK£23.3m

7D

-6.1%

1Y

-54.6%

Updated

27 Sep, 2022

Data

Company Financials +
POLB fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

POLB Stock Overview

Poolbeg Pharma plc operates as a clinical stage infectious disease pharmaceutical company in the United Kingdom.

Poolbeg Pharma PLC Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Poolbeg Pharma
Historical stock prices
Current Share PriceUK£0.046
52 Week HighUK£0.12
52 Week LowUK£0.04
Beta0
1 Month Change3.33%
3 Month Change-17.70%
1 Year Change-54.63%
3 Year Changen/a
5 Year Changen/a
Change since IPO-56.74%

Recent News & Updates

Jul 12
Here's Why We're Not Too Worried About Poolbeg Pharma's (LON:POLB) Cash Burn Situation

Here's Why We're Not Too Worried About Poolbeg Pharma's (LON:POLB) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

POLBGB PharmaceuticalsGB Market
7D-6.1%-1.3%-3.1%
1Y-54.6%-1.3%-14.5%

Return vs Industry: POLB underperformed the UK Pharmaceuticals industry which returned -2% over the past year.

Return vs Market: POLB underperformed the UK Market which returned -14.6% over the past year.

Price Volatility

Is POLB's price volatile compared to industry and market?
POLB volatility
POLB Average Weekly Movement9.0%
Pharmaceuticals Industry Average Movement6.7%
Market Average Movement5.3%
10% most volatile stocks in GB Market10.8%
10% least volatile stocks in GB Market2.6%

Stable Share Price: POLB is more volatile than 75% of UK stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: POLB's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of UK stocks.

About the Company

FoundedEmployeesCEOWebsite
20217Jeremy Skillingtonhttps://www.poolbegpharma.com

Poolbeg Pharma plc operates as a clinical stage infectious disease pharmaceutical company in the United Kingdom. It develops POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an inlicensed firstinclass intranasally administered RNAbased immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis. The company also has a licensed access to micro and nanoencapsulation technology to develop an oral vaccine delivery platform that delivers immune stimulating antigens to various areas of the gut; and artificial intelligence powered drug program.

Poolbeg Pharma PLC Fundamentals Summary

How do Poolbeg Pharma's earnings and revenue compare to its market cap?
POLB fundamental statistics
Market CapUK£23.25m
Earnings (TTM)-UK£3.11m
Revenue (TTM)n/a

0.0x

P/S Ratio

-7.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
POLB income statement (TTM)
RevenueUK£0
Cost of RevenueUK£0
Gross ProfitUK£0
Other ExpensesUK£3.11m
Earnings-UK£3.11m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.0062
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did POLB perform over the long term?

See historical performance and comparison